Trial · NCT03078478
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) | Insulin Degludec 200 | 216.8 | Episodes/(PYE*100) | ||
| Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) | Insulin Glargine U300 | 243.9 | Episodes/(PYE*100) | ||
| Basal Insulin Dose (U) at End of Treatment (up to 88 Weeks) | Insulin Degludec 200 | 66.6 | Standard Deviation 48.54 | Units | |
| Basal Insulin Dose (U) at End of Treatment (up to 88 Weeks) | Insulin Glargine U300 | 73.0 | Standard Deviation 48.48 | Units | |
| Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) | Insulin Degludec 200 | 62.30 | Episodes/(PYE*100) | ||
| Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) | Insulin Glargine U300 | 93.75 | Episodes/(PYE*100) | ||
| Number of Severe Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) | Insulin Degludec 200 | 0.98 | Episodes/(PYE*100) | ||
| Number of Severe Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) | Insulin Glargine U300 | 4.88 | Episodes/(PYE*100) | ||
| Change in HbA1c From Baseline to End of Treatment (up to 88 Weeks) | Insulin Degludec 200 | -0.54 | Standard Deviation 0.91 | Percentage of HbA1c | |
| Change in HbA1c From Baseline to End of Treatment (up to 88 Weeks) | Insulin Glargine U300 | -0.46 | Standard Deviation 0.90 | Percentage of HbA1c | |
| Change in Fasting Plasma Glucose (FPG) From Baseline to End of Treatment (up to 88 Weeks) | Insulin Degludec 200 | -35.50 | Standard Deviation 49.34 | mg/dL | |
| Change in Fasting Plasma Glucose (FPG) From Baseline to End of Treatment (up to 88 Weeks) | Insulin Glargine U300 | -25.68 | Standard Deviation 56.69 | mg/dL | |
| Percentage of Participants With FPG ≤ 7.2 mmol/L (130 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no) | Insulin Degludec 200 | Yes | 84.0 | Percentage of participants | |
| Percentage of Participants With FPG ≤ 7.2 mmol/L (130 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no) | Insulin Glargine U300 | Yes | 72.0 | Percentage of participants | |
| Percentage of Participants With FPG ≤ 7.2 mmol/L (130 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no) | Insulin Degludec 200 | No | 16.0 | Percentage of participants | |
| Percentage of Participants With FPG ≤ 7.2 mmol/L (130 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no) | Insulin Glargine U300 | No | 28.0 | Percentage of participants | |
| Percentage of Participants With FPG ≤ 5.0 mmol/L (90 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no) | Insulin Degludec 200 | Yes | 31.5 | Percentage of participants | |
| Percentage of Participants With FPG ≤ 5.0 mmol/L (90 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no) | Insulin Glargine U300 | Yes | 21.7 | Percentage of participants | |
| Percentage of Participants With FPG ≤ 5.0 mmol/L (90 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no) | Insulin Degludec 200 | No | 68.5 | Percentage of participants | |
| Percentage of Participants With FPG ≤ 5.0 mmol/L (90 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no) | Insulin Glargine U300 | No | 78.3 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03078478/results